Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 29

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 29
---
.                              |

Beneficial owners of shares held in “street name” may change their voting instructions only by following the directions received from their bank, brokerage firm or other nominee for changing their voting instructions.

| Q: | What happens if I sell my shares of Enfusion Common Stock before the Special Meeting? |

| A: | The record date is earlier than both the date of the Special Meeting and the Closing of the Transactions. If                                                                                                                                       
 you transfer your shares of Enfusion Common Stock after the record date but before the Special Meeting, you will, unless the transferee requests a proxy from you, retain your right to vote at the Special Meeting but will transfer the right to 
 receive the Merger Consideration to the person to whom you transfer your shares. In order to receive the Merger Consideration, you must hold your shares upon completion of the Transactions.                                                      |

| Q: | Do Enfusion Stockholders have appraisal rights? |

| A: | Yes. Enfusion Stockholders are entitled to appraisal rights under Section 262 of the Delaware General                                                                                                                            
 Corporation Law (the “DGCL”) in connection with the Merger provided they follow the procedures and satisfy the conditions set forth in Section 262 of the DGCL. For more information regarding appraisal rights, see the section 
 titled “Appraisal Rights of Enfusion Stockholders.” In addition, a copy of Section 262 of the DGCL is attached as Annex E to this Proxy Statement/Prospectus. Failure to strictly comply with Section 262 of the DGCL may        
 result in your waiver of, or inability to, exercise appraisal rights.                                                                                                                                                            |

| Q: | Who will solicit and pay the cost of soliciting proxies? |

| A: | Enfusion will pay for the proxy solicitation costs related to the Special Meeting. Enfusion has engaged                                                                   
 Innisfree to assist in the solicitation of proxies for the Special Meeting. Enfusion estimates that it will pay Innisfree a fee of approximately $20,000, plus reasonable 
 out-of-pocket expenses. Enfusion will also reimburse banks, brokerage firms, custodians, trustees, nominees and fiduciaries who hold shares for the benefit of another    
 party for their expenses incurred in sending proxies and proxy materials to beneficial                                                                                    |

11

| owners of Enfusion Common Stock. Enfusion’s directors, officers and employees also may solicit proxies in person by telephone or over the Internet. They will not be paid any additional 
 amounts for soliciting proxies.                                                                                                                                                          |

| Q